Induction of a robust immunity response against novel duck reovirus in ducklings using a subunit vaccine of sigma C protein

被引：31

作者：

Bi, Zhuangli ^{[1
,2
]}

Zhu, Yingqi ^{[1
,2
]}

Chen, Zongyan ^{[1
]}

Li, Chuanfeng ^{[1
]}

Wang, Yong ^{[2
]}

Wang, Guijun ^{[2
]}

Liu, Guangqing ^{[1
]}

机构：

[1] Chinese Acad Agr Sci, Shanghai Vet Res Inst, Shanghai 200241, Peoples R China

[2] Anhui Agr Univ, Coll Anim Sci & Technol, Hefei 230036, Peoples R China

来源：

SCIENTIFIC REPORTS | 2016年 / 6卷

关键词：

COMPLETE GENOMIC SEQUENCE; AVIAN REOVIRUS; PEKIN DUCKLINGS; ORIGIN REOVIRUS; INFECTION; PATHOGENICITY; BACULOVIRUS; EXPRESSION; DELIVERY; DISEASE;

D O I：

10.1038/srep39092

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Novel duck reovirus (NDRV) disease emerged in China in 2011 and continues to cause high morbidity and about 5.0 to 50% mortality in ducklings. Currently there are no approved vaccines for the virus. This study aimed to assess the efficacy of a new vaccine created from the baculovirus and sigma C gene against NDRV. In this study, a recombinant baculovirus containing the sigma C gene was constructed, and the purified protein was used as a vaccine candidate in ducklings. The efficacy of sigma C vaccine was estimated according to humoral immune responses, cellular immune response and protection against NDRV challenge. The results showed that sigma C was highly expressed in Sf9 cells. Robust humoral and cellular immune responses were induced in all ducklings immunized with the recombinant sigma C protein. Moreover, 100% protection against lethal challenge with NDRV TH11 strain was observed. Summary, the recombinant sigma C protein could be utilized as a good candidate against NDRV infection.

引用

页数：11

共 54 条

[1] Pekin and Muscovy ducks respond differently to vaccination with a H5N1 highly pathogenic avian influenza (HPAI) commercial inactivated vaccine [J].

Cagle, Caran ;

Thanh Long To ;

Tung Nguyen ;

Wasilenko, Jamie ;

Adams, Sean C. ;

Cardona, Carol J. ;

Spackman, Erica ;

Suarez, David L. ;

Pantin-Jackwood, Mary J. .

VACCINE, 2011, 29 (38) :6549-6557

[2] Commercial porcine circovirus type 2 vaccines: Efficacy and clinical application [J].

Chae, Chanhee .

VETERINARY JOURNAL, 2012, 194 (02) :151-157

[3]

Chen S., 2012, FUJIAN J AGR SCI, V27, P461

[4] Outbreak-associated Novel Duck Reovirus, China, 2011 [J].

Chen, Zongyan ;

Zhu, Yinqi ;

Li, Chuanfong ;

Liu, Guangqing .

EMERGING INFECTIOUS DISEASES, 2012, 18 (07) :1209-1211

[5] Reovirus infection in two species of Psittaciformes recently imported into Italy [J].

Conzo, G ;

Magnino, S ;

Sironi, G ;

Lavazza, A ;

Vigo, PG ;

Fioretti, A ;

Kaleta, EF .

AVIAN PATHOLOGY, 2001, 30 (01) :43-47

[6] A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) Vaccine [J].

Couch, Robert B. ;

Patel, Shital M. ;

Wade-Bowers, Chianti L. ;

Nino, Diane .

PLOS ONE, 2012, 7 (12)

[7]

Ding M., 2016, CHINESE J ANIMAL INF, V24, P7

[8] Immunogenicity of empty capsids of porcine circovius type 2 produced in insect cells [J].

Fan, H. ;

Ju, C. ;

Tong, T. ;

Huang, H. ;

Lv, J. ;

Chen, H. .

VETERINARY RESEARCH COMMUNICATIONS, 2007, 31 (04) :487-496

[9] Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins [J].

Fort, M. ;

Sibila, M. ;

Allepuz, A. ;

Mateu, E. ;

Roerink, F. ;

Segales, J. .

VACCINE, 2008, 26 (08) :1063-1071

[10]

GLAVITS R, 1984, ACTA VET HUNG, V32, P23

← 1 2 3 4 5 6 →